Latest Administration News

Genesis Minerals has tabled a binding offer to acquire Vault Minerals for approximately $5.6 billion, outbidding a prior scheme with Regis Resources and triggering a five-day matching period.

Genesis Minerals has disrupted the proposed Vault-Regis merger with a superior $5.6 billion takeover bid, offering Vault shareholders a mix of cash and shares. Regis Resources meanwhile reported strong FY26 production hitting the top end of guidance, underpinning its robust cash position.

European Lithium and Critical Metals Corp. have amended their merger agreement, introducing a sale facility option for small shareholders and switching to direct share issuance, aiming for scheme implementation in October 2026.

Orthocell has secured a strategic foothold in Thailand's $84 million nerve repair sector by appointing MediTime as exclusive Remplir distributor, leveraging established clinical networks to accelerate market penetration.

OncoSil Medical has submitted its Humanitarian Device Exemption application to the FDA for its OncoSil™ device targeting distal cholangiocarcinoma, entering the final review phase with a decision expected within 45 days.

Telix Pharmaceuticals has gained FDA alignment to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer, setting the stage for U.S. enrolment pending regulatory approval.

Neurotech International has received Notices of Allowance from the USPTO for two patents covering its lead drug NTI164, reinforcing its intellectual property position as it advances Phase 3 trials for autism spectrum disorder.

Bowen Coking Coal's entire shareholding and options have been transferred to Argo Bowen 2 following a court-approved Deed of Company Arrangement, marking a key step in the company’s restructuring.

Imugene reports a second complete response in its Phase 1b trial of azer-cel combined with BTK inhibitors, including the first patient with Mantle Cell Lymphoma who had failed prior BTKi therapy.

Mesoblast has received a Biologics License Application filing number from the FDA for rexlemestrocel-L, targeting life-threatening bleeding in end-stage heart failure patients with LVADs, advancing its regulatory journey with orphan drug and RMAT designations.

Global X Management (AUS) Limited is trimming the management fee for its Australia 300 ETF (ASX: A300) by 25%, effective 1 July 2026, reflecting a subtle but meaningful cost saving for investors.

AdAlta has met a key US$1 million milestone payment under its China collaboration, gaining critical clinical data and securing proprietary materials for Australian manufacturing of its lead CAR-T therapy BZDS1901.